IP Library Granted Patent US 9,758,590
Granted Patent B2
US 9,758,590 · App. 14/958,980 · Granted Sep 12, 2017

Anti-CD38 human antibodies and uses thereof

Inventors: Michael Tesar (Friedberg, DE); Ute Jaeger (Munich, DE)
Assignee: MORPHOSYS AG
C07K16/2896C07K16/005C07K16/3061C07K16/40C12N9/2497C12Y302/02024A61K2039/505C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/52C07K2317/55C07K2317/56C07K2317/565C07K2317/567C07K2317/732C07K2317/734C07K2317/74C07K2317/92C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,758,590
App. No.
14/958,980
Granted
Sep 12, 2017
Kind
B2
Abstract

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.

Claims (3)

1. An isolated human monoclonal anti-CD38 antibody comprising a framework sequence, a VH3 heavy chain, a kappa light chain, an IgG1 constant region, and six complementarity determining regions, wherein said antibody binds to VSRRFAEAACDVVHV (SEQ ID NO: 38).

2. The antibody according to claim 1 , wherein the VH3 heavy chain region comprises a framework 1 region comprising SGGGLVQPGGSLRLSC (SEQ ID NO: 44), a framework 2 region comprising VRQAPGKGLEW (SEQ ID NO: 45), a framework 3 region comprising FTISRDNSKNTLYLQMNSLRAEDTAV (SEQ ID NO: 46) and a framework 4 region comprising GQGTLVTV (SEQ ID NO: 47).

3. The antibody according to claim 1 , wherein the kappa light chain region comprises a framework 1 region comprising TQSP (SEQ ID NO: 48), a framework 2 region comprising QKPG (SEQ ID NO: 49), a framework 3 region comprising RFSGSGSGTDFTL (SEQ ID NO: 50) and a framework 4 region comprising TFGQGTKVEIK (SEQ ID NO: 51).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2017
From: TESAR, MICHAEL; JÄGER, UTE
To: MORPHOSYS AG
Reel/Frame 042943/0804 →
Continuity (9)
Continuation 14630042 · Feb 24, 2015
Continuation 13427305 · Mar 22, 2012
Division 10588568
Provisional Application 60541911 · Feb 6, 2004
Provisional Application 60547584 · Feb 26, 2004
Provisional Application 60553948 · Mar 18, 2004
Provisional Application 60599014 · Aug 6, 2004
Provisional Application 60614471 · Oct 1, 2004
Related Publication 20160115243A1 · Apr 28, 2016